Homeopathic treatment for warty non cancerous growth of the voice box

Double blind, placebo controlled, randomized, controlled trial to evaluate the efficacy of adjuvant treatment with homeopathic medication thuja (arbor vitae) in decreasing severity and decreasing post-surgical recurrence in recurrent respiratory papillomatosis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/12/002277

Enrollment

Registered

2011-12-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Papillomatous lesion of the respiratory tract

Interventions

Intervention1: Arbor vitae(Thuja)administered as sugar coated homeopathic pills: The medicine will be given in a dose of Thuja 30 orally BD for a duration of 20 weeks Control Intervention1: Placebo:

Eligibility

Inclusion criteria

Inclusion criteria: 1. Papillomatous lesion of the respiratory tract. 2. Primary as well as recurrent lesions shall be included. 3. Informed consent of patient for study participation and for regular clinical review.

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Breast feeding 3. Hepatic or renal impairment as indicated by baseline biochemical testing. 4. Use of alternate systemic or topical medications for respiratory Papillomatosis. 5. Significant uncontrolled systemic illness.

Design outcomes

Primary

Measure	Time frame
1. Derkay papilloma severity grading score 2. Voice handicap index 3. HPV genotyping 4. Viral load quantificationTimepoint: Presurgical evaluation at 4 and 8 weeks Postsurgical evaluation at 4,8,12 and 20 weeks	—

Secondary

Measure	Time frame
HPV Viral load quantificationTimepoint: 8 weeks after initiation of drug	—

Countries

India

Contacts

Public ContactDr Alok Thakar

AIIMS

drathakar@gmail.com9868397471

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026